Paclitaxel-Coated Balloon Versus Plain Balloon Angioplasty for Hemodialysis Access Maintenance: A Systematic Review and Updated Meta-analysis

Xiyang Chen,Yang Liu,Jiarong Wang,Jichun Zhao,Niten Singh,Wayne Zhang
DOI: https://doi.org/10.1016/j.jvs.2020.04.035
IF: 4.86
2020-01-01
Journal of Vascular Surgery
Abstract:The comparison between paclitaxel-coated balloon (PCB) angioplasty and plain balloon angioplasty (PBA) for hemodialysis (HD) access stenosis or occlusion has not been well investigated. The objectives of this systematic review and meta-analysis were to compare the all-cause mortality, HD access primary patency, and circuit primary patency after endovascular maintenance procedures using PCB vs PBA. MEDLINE, Embase, and Cochrane databases were systematically searched to identify all the relevant studies on paclitaxel-coated devices for the stenosis or thrombosis of HD access. A random effects model was applied to pool the effect measures. Dichotomous data were presented using an odds ratio (OR). Effect data were presented using pooled hazard ratio (HR) with 95% confidence interval (CI). A total of 16 studies were included in this meta-analysis, 12 randomized clinical trials and 4 cohort studies involving 1086 patients who underwent endovascular treatment for HD access stenosis or occlusion. All-cause mortality rates at 6, 12, and 24 months after intervention were similar between PCB and PBA groups (6 months: OR, 1.06 [95% CI, 0.38-2.96; P = .907; I2 = 19.2%]; 12 months: OR, 1.20 [95% CI, 0.66-2.16; P = .554; I2 = 0%]; 24 months: OR, 1.43 [95% CI, 0.83-2.45; P = .195; I2 = 0%]; Fig 1). There was a significant improvement of primary patency in the PCB group compared with the PBA group (HR, 0.47; 95% CI, 0.33-0.69; P < .001; I2 = 67.3%). This benefit was consistent with the analysis of randomized clinical trials, whereas cohort studies were excluded. Further subgroup analysis on target lesions demonstrated that the primary patency was significantly higher in the PCB group than in the PBA group, not only for arteriovenous fistula (HR, 0.54; 95% CI, 0.30-0.98; P = .041; I2 = 76.8%) but also for central venous stenosis (HR, 0.29; 95% CI, 0.10-0.86; P = .002; I2 = 0%; Fig 2). Circuit primary patency analysis showed a marginal trend toward better outcome in the PCB (HR, 0.63; 95% CI, 0.40; 1.00) group but no statistical significance (P = .052). This systematic review and meta-analysis demonstrated that PCB angioplasty is associated with significantly improved primary patency of arteriovenous fistula and central venous stenosis for HD access maintenance, with no evidence of increasing all-cause mortality at the 6-, 12-, and 24-month follow-up.Fig 2Forest plot showing the hazard ratios (HRs) for lesion primary patency by study design (A) and lesion type (B) in subgroup analyses.View Large Image Figure ViewerDownload Hi-res image Download (PPT)
What problem does this paper attempt to address?